Trial Profile
Evaluation of the behavior of platelets count, EGF serum concentrations and the levels of lymphocytes subpopulations expression associated with the patient's immune status as possible biomarkers of effectiveness of CIMAvax-EGF vaccine.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs BV NSCLC 001 (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Oct 2020 Randomised allocation removed from the study protocol.
- 13 Nov 2018 New trial record